Role of matrix metalloproteinases in melanoma cell invasion

被引：136

作者：

Hofmann, UB ^{[1
]}

Houben, R ^{[1
]}

Bröcker, EB ^{[1
]}

Becker, JC ^{[1
]}

机构：

[1] Univ Wurzburg, Dept Dermatol, D-97080 Wurzburg, Germany

来源：

BIOCHIMIE | 2005年 / 87卷 / 3-4期

关键词：

matrix metalloproteinases; tissue inhibitor of matrix metalloproteinases; adhesion molecules; tumor-stromal interaction; microenvironment; melanoma progression;

D O I：

10.1016/j.biochi.2005.01.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cutaneous melanomas are notorious for their tendency to metastasize. Essential steps in this process are the degradation of basement membranes and remodeling of the extracellular matrix (ECM) by proteolytic enzymes such as matrix metalloproteinases (MMPs), which are regulated by their tissue inhibitors (TIMPs). An NIMP expression is not restricted to tumor cells but is also found in stromal cells, indicating that stroma-derived proteases may contribute to melanoma progression. The MMPs have been shown to interact with a broad range of non-matrix proteins including adhesion molecules, growth factors and mediators of angiogenesis and apoptosis. In this review, we evaluate new insights into the interplay of MMPs and their molecular partners in rnelanoma progression. (c) 2005 Elsevier SAS. All rights reserved.

引用

页码：307 / 314

页数：8

共 105 条

[71]

Nagase H, 1997, BIOL CHEM, V378, P151

[72]

Naglich JG, 2001, CANCER RES, V61, P8480

[73] Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion [J].

Nakahara, H ;

Howard, L ;

Thompson, EW ;

Sato, H ;

Seiki, M ;

Yeh, YY ;

Chen, WT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (15) :7959-7964

[74] TIMP-2 growth-stimulatory activity: A concentration- and cell type-specific response in the presence of insulin [J].

Nemeth, JA ;

Rafe, A ;

Steiner, M ;

Goolsby, CL .

EXPERIMENTAL CELL RESEARCH, 1996, 224 (01) :110-115

[75] High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma [J].

Nikkola, J ;

Vihinen, P ;

Vlaykova, T ;

Hahka-Kemppinen, M ;

Kähäri, VM ;

Pyrhönen, S .

INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (04) :432-438

[76] Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules [J].

Ohuchi, E ;

Imai, K ;

Fujii, Y ;

Sato, H ;

Seiki, M ;

Okada, Y .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (04) :2446-2451

[77] Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin - A possible cell surface activator [J].

Okumura, Y ;

Sato, H ;

Seiki, M ;

Kido, H .

FEBS LETTERS, 1997, 402 (2-3) :181-184

[78] Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity [J].

Pei, DQ ;

Weiss, SJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (15) :9135-9140

[79] Phase II study of marimastat (BB-2516) in malignant melanoma - A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group [J].

Quirt, I ;

Bodurtha, A ;

Lohmann, R ;

Rusthoven, J ;

Belanger, K ;

Young, V ;

Wainman, N ;

Steward, W ;

Eisenhauer, E .

INVESTIGATIONAL NEW DRUGS, 2002, 20 (04) :431-437

[80] Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat [J].

Rasmussen, HS ;

McCann, PP .

PHARMACOLOGY & THERAPEUTICS, 1997, 75 (01) :69-75

← 2 3 4 5 6 7 8 9 10 11 →